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Volume 59, Number 6S Abstracts 87Swithout a change in diameter at day 1; however, shear stress
was normalized by day 7. Patency was 100% and survival was
diminished by 50% in these large AVFs. Shear stress in AVFs
created with the 28-gauge needle was decreased by 39% but
AVF patency was reduced 50%. Survival was 100%.
Conclusions: This murine aortocaval model faithfully
recapitulates the maturation and failure phases of the human
AVF; this is the ﬁrst animal model to show these distinct
phases. Shear stress varies according to the diameter of the
ﬁstula. and AVF patency depends on the AVF shear stress.
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Objectives: Contrast-induced nephropathy (CIN) is the
third leading cause of hospital-acquired renal failure. Early
diagnosis and treatment of CIN may prevent signiﬁcant
sequelae. It has been reported that urinary ﬁbrinogen (Fg)
can be used as a biomarker of ischemia-reperfusion injury in
kidney. The objective of this study was to investigate whether
urinary Fg can serve as a biomarker for the diagnosis of CIN.
Methods: C57B1/6J mice received a prostaglandin
synthesis inhibitor (indomethacin, 10 mg/kg) and a nitric
oxide synthase inhibitor (Nu-Nitro-L-arginine methyl ester,
10 mg/kg) intraperitoneally (i.p.), before being given iodix-
anol in low-dose (6.24 g iodine/mL i.p.) and high-dose
(12.48 g iodine/kg i.p.) groups. Mice in the control group
received normal saline instead of iodixanol. Urine samples
were collected for Fg and creatinine (Cr) analysis using an
enzyme-linked immunosorbent assay kit. Kidneys were har-
vested 24 hours later. RNA was extracted from half of a kid-
ney specimen. Quantitative RT-PCR was used to quantify
Fg-a RNA expression, with glyceraldehyde-3-phosphate de-
hydrogenase as the endogenous control. The other half of
the kidney specimen was ﬁxed with formalin, embedded in
parafﬁn, and then stained with hematoxylin and eosin
(H&E) for histopathologic evaluation.
Results: H&E stain demonstrated mild renal injury in
the low-dose group, scoring from 0 to 1, and moderate
renal injury in high-dose group scoring from 1 to 2, based
on a pathologic grading scale of 0 to 3. Urinary Fg
increased signiﬁcantly from 0.37 6 0.13 mg/mg Cr in
the control group to 3.46 6 2.89 mg/mg Cr in the
low-dose group (P < .05) and 6.15 6 2.51 mg/mg Cr
in the high-dose group (P < .01). Fg-a RNA level
increased 40% in high-dose group compared with the con-
trol (P < .05), although no signiﬁcant changes were
detected in the low-dose group.Conclusions: Urinary Fg level increases are consistent
with the pathologic severity of CIN in animal models.
These results suggest that urinary Fg may be a potential
biomarker for early diagnosis of CIN. Further investigation
in clinical patients is needed.
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Objectives: Free radicals have been implicated in myo-
nephropathic metabolic syndrome (MNMS), which dam-
ages not only muscles but also kidneys. At Vascular
Annual Meeting (VAM) 2012, we reported the free radical
scavenger, edaravone (Radicut, Mitsubishi Tanabe Pharma
Co, Japan), suppresses muscle injury by MNMS. In this
study, we evaluated whether edaravone can suppress kidney
damage by MNMS.
Methods: Lewis male rats (508 6 31 g, n ¼ 10)
were intraperitoneally injected with 3.0 mg/kg of edar-
avone (edaravone group [n ¼ 4]), or saline (MNMS
group [n ¼ 6]). The MNMS models were induced by
clamping the bilateral common femoral arteries for 5
hours and then declamping. Five hours after declamping,
the both kidneys were stained with hematoxylin and
eosin (Fig). Normal kidneys were harvested as a control
(n ¼ 3). Kidney damage was evaluated by the number of
cells in the glomerulus (glomerulus inﬁltration) and by
the number of residual tubular cells (enlargement of
tubular cells).
Results: The number of cells in the glomerulus was
signiﬁcantly increased in the MNMS group compared
with the control (77.2 6 10.3 vs 49.6 6 2.8 cells/
glomerulus, P < .01). The number of cells in the
